CompletedNo phase
The Isthmus Logic Post Market Clinical Follow-up Study
Key facts
- Who runs it
- CID S.p.A.
- Where
- Italy1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 37 people enrolled
- Started
- 4 Sept 2023
- Ended
- 22 May 2024
- Type of study
- Observational
- Treatments tested
- Isthmus Logic
- Record updated
- 22 October 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Patient has been implanted with at least one Isthmus Logic stent according to the indications described in the Instructions for Use (IFU)
- Study device implantation date is at least one year (12 months) prior to the starting date of the retrospective anonymous data collection
Who cannot take part
- Patients treated less than 12 months prior to study start
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Isthmus Logic Carbostent™ is a CE-marked cobalt chromium stent with a bio inducer surface for the treatment of peripheral iliac artery disease.
Read full original descriptionShow less
The aim of this post-market retrospective study protocl P22202 is to collect clinical data of patients treated with Isthmus Logic for the treatment of peripheral iliac artery disease in routine clinical practice.
In order to obtain long-term follow-up data, the data collection will be limited to patients that have been treated with these devices at least 12 months prior to the study start.
Treatments tested
- Isthmus Logic
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Cobalt Chromium Stent With a Bio Inducer Surface for the Treatment of Peripheral Iliac Artery Disease: Evaluation of Safety and Performance in Everyday Clinical Practice. The Isthmus Logic Post Market Clinical Follow-up Study.
- Record updated
- 22 October 2026